Highlights Pfizer Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 18/05/2026 BST			After hours 01:00:00
25.33 ^USD	0.00%		25.89	+2.21%

05-18	US states reject anti-vaccine bills as public health groups fight MAHA	RE
05-18	Daiwa Securities Adjusts Price Target on Pfizer to $28 From $27, Maintains Neutral Rating	MT

Highlights

05-13	Pfizer Inc Approves Hympavzi for Treatment of Adults and Adolescents with Hemophilia A or B with Inhibitors	CI
05-13	European Commission approves Pfizer's Hympavzi for the treatment of adults and adolescents with hemophilia A or B with inhibitors	RE
05-13	Pfizer Says European Commission Approves Expanded Indication for Hympavzi	MT
05-07		FA
05-05	Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC	MT
05-05	Health Care Up After Earnings - Health Care Roundup	DJ
05-05	Pfizer Tops First-Quarter Estimates, Reaffirms Full-Year Outlook	MT
05-05	Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 29, 2026	CI
05-05	Pfizer Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Pfizer 1Q Revenue Rises But Profit Falls Amid Boosted R&D Spending	DJ
05-05	Pfizer Q1 Adjusted Earnings Fall, Revenue Rises	MT
05-05	(PFE) Pfizer Expects 2026 Revenue Range $59.5B to $62.5B, vs. FactSet Est of $61.38B	MT
05-05	Earnings Flash (PFE) Pfizer Inc. Reports Q1 Revenue $14.45B, vs. FactSet Est of $13.84B	MT
05-05	Earnings Flash (PFE) Pfizer Inc. Posts Q1 Adjusted EPS $0.75 per Share, vs. FactSet Est of $0.72	MT
05-05	(PFE) Pfizer Expects 2026 Adjusted EPS Range $2.80 to $3.00, vs. FactSet Est of $2.96	MT
05-05	Pfizer pins post 2028 return to growth on new obesity and cancer drugs	RE
05-05	Tranche Update on Pfizer Inc.'s Equity Buyback Plan announced on December 14, 2018.	CI
05-05	Pfizer beats first-quarter profit estimates on strong demand for blood thinner Eliquis	RE
05-05	BioNTech to close sites in Germany, Singapore affecting 1,860 staff	RE
05-05	Pfizer Inc. Reaffirms Earnings Guidance for the Full-Year 2026	CI
04-29	Pfizer's blood cancer drug meets main goal in late-stage trial	RE
04-29	Pfizer Inc Announces Positive Topline Results from Phase 3 MagnetisMM-5 Study Evaluating Elrexfio as Monotherapy in Adults with Relapsed or Refractory Multiple Myeloma	CI
04-28	Pfizer secures deals to keep heart drug free of generic rivals until 2031	RE
04-28	Pfizer secures deals to keep heart drug free of generic rivals until 2031	RE
04-28	Pfizer reaches settlement agreements with Dexcel Pharma, Hikma & Cipla for Vyndamax	RE